Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
In this study, the investigators aim to use data identified through the hospital's integrated medical database and National Health Insurance database to explore the long-term performance and benefits of biological and mechanical valves. This research aims to provide more recommendations and references for valve replacement in different patient populations.
Long-term follow-up of valve surgery is essential in all cardiac surgeries and is the most commonly discussed indicator. The choice of valves has evolved over the past 30 years, offering two options: biological valves and mechanical valves. Biological valves have seen advancements in the last 15 years, including new processes and improved valve preservation methods. The question of whether these new process valves offer better long-term effectiveness has become a hot research topic in recent years.
Mechanical valves have a longer lifespan, but the need for long-term anticoagulant use to prevent mechanical valve thrombosis has raised concerns about anticoagulant side effects, abnormal clotting function, and bleeding. Biological valves, on the other hand, do not require long-term anticoagulation and only necessitate 2-3 months of anticoagulant treatment. However, the risk of biological valve degeneration results in an average lifespan of 10 to 20 years, which cannot match the durability of mechanical valves. This is the drawback of using biological valves.
Therefore, the investigators hope to utilize the hospital's integrated medical database and the long-term National Health Insurance database for tracking. The investigators aim to observe valve performance in different patient groups, such as young people, the elderly, patients on dialysis, those with rheumatic autoimmune diseases, and those taking specific medications, among others.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Bioprothetic valve | Groups undergoing cardiac valve surgery with bioprothetic valve. |
| |
| Mechanical valve | Groups undergoing cardiac valve surgery with mechanical valves. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| valve | Other | bioprothetic valve versus mechanical valve |
|
| Measure | Description | Time Frame |
|---|---|---|
| all-cause mortality | included estimated survival using a Cox regression model. Survival data were obtained for all NHIRD databases. Operative mortality was defined as death during the index hospitalization or within 30 days of the operation. Long-term survival data included death from all causes. survival outcome was measured months after the index operation. | 1998-2019 |
| Measure | Description | Time Frame |
|---|---|---|
| composite outcome and individual component of major adverse prosthesis-related events, including death, major bleeding, ischemic stroke, endocarditis, and aortic valve reoperation | each of which were defined as an emergency room visit or hospital admission with related diagnosis codes as the primary diagnosis | 1998-2019 |
Not provided
Inclusion Criteria:This is a retrospective study, and we plan to utilize data from the hospital's integrated medical database and the National Health Insurance database from January 2007 to December 2019. We will identify all patients within the data who were diagnosed with valve diseases and underwent valve replacement surgery.
-
Exclusion Criteria:Individuals under 20 years of age.
-
Not provided
Not provided
Not provided
A total of 30,000 individuals (including this institution and other domestic units).
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Nai-Hsin Chi | Contact | 886-2-23123456 | 265081 | chinaihsin@gmail.com |
| Name | Affiliation | Role |
|---|---|---|
| Nai-Hsin Chi | attending physician | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| National Taiwan University Hospital | Recruiting | Taipei | 100 | Taiwan |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 38995189 | Derived | Takei Y, Chou NK, Wei LY, Fu HY, Yu HY, Chi NH. Robotic transmitral approach in hypertrophic cardiomyopathy. Int J Surg. 2024 Nov 1;110(11):7391-7394. doi: 10.1097/JS9.0000000000001934. No abstract available. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D006349 | Heart Valve Diseases |
| ID | Term |
|---|---|
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided